Patents Examined by Lea S O'Brien
  • Hydrophobic interaction chromatography for viral clearance
    Patent number: 12234277
    Abstract: The present application provides a method for characterizing and/or determining viral clearance capacity of hydrophobic interaction chromatography (HIC) including experimental design for multivariate analysis of viral clearance of HIC. The method provides understanding of the mechanism of the viral clearance using HIC by running a D-Optimal design of experiment including evaluations of multiple factors, such as pH, buffer concentration, column loading concentration, flow rate of column, or hydrophobic strength of the HIC column.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: February 25, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: John Ruppino, John Mattila, Robert Stairs
  • Antibodies that bind human C6 and uses thereof
    Patent number: 12194091
    Abstract: Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: January 14, 2025
    Assignee: REGENESANCE B.V.
    Inventors: Frank Baas, Marc A. Van Dijk
  • IL3Ralpha antibodies and uses thereof
    Patent number: 12187802
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: January 7, 2025
    Assignee: Stemline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Humanized anti-human neurotensin receptor 1 antibodies and their uses
    Patent number: 12091454
    Abstract: A humanized anti-neurotensin receptor 1 (NTSR1) antibody or an antigen-binding fragment thereof. Also, a method for treating, prophylactic treating and/or preventing diseases and/or disorders caused by or related to NTSR1 activity and/or signaling, and a method or kit for detecting NTSR1 in a sample.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: September 17, 2024
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Cheng-Chou Yu, Shu-Ping Yeh, Chao-Yang Huang, Szu-Liang Lai, Shih-Liang Hsiao, Mei-Ling Hou, Tzung-Jie Yang, Wei-Ting Sun, Liang-Yu Hsia, Andrew Yueh, Chiung-Tong Chen, Ren-Huang Wu, Pei-Shan Wu, Han-Shu Hu, Tzu-Chin Wu, Jia-Ni Tian
  • Antibodies specific to delta 1 chain of T cell receptor
    Patent number: 12084500
    Abstract: Disclosed herein are antibodies specific to a delta-1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 10, 2024
    Assignees: New York University, PureTech LYT, Inc.
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko, Takamitsu Hattori, Aleksandra Filipovic, Eric Elenko, Joseph Bolen
  • Anti-ULBP6 antibodies
    Patent number: 12060426
    Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: August 13, 2024
    Assignee: 23andMe, Inc.
    Inventors: Joel Benjamin, Shashank Bharill, I-Ling Chen, Yu Chen, Wei-Jen Chung, Zahra Bahrami Dizicheh, Germaine Fuh, Patrick Koenig, Yujie Liu, Mauro Poggio, Shruti Yadav, Ping-Chiao Tsai, Claus Spitzfaden
  • Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereof
    Patent number: 12037396
    Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: July 16, 2024
    Assignee: Nanjing GenScript Biotech Co., Ltd.
    Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu